Open Access Highly Accessed Open Badges Research article

Differential expression of selected histone modifier genes in human solid cancers

Hilal Özdağ12, Andrew E Teschendorff1, Ahmed Ashour Ahmed1, Sarah J Hyland1, Cherie Blenkiron15, Linda Bobrow3, Abhi Veerakumarasivam1, Glynn Burtt1, Tanya Subkhankulova1, Mark J Arends3, V Peter Collins3, David Bowtell6, Tony Kouzarides4, James D Brenton15 and Carlos Caldas15*

Author Affiliations

1 Cancer Genomics Program, Department of Oncology, Hutchison/MRC Research Centre, University of Cambridge, Cambridge CB2 2XZ, UK

2 Ankara University, Institute of Biotechnology, Beşevler 06500 Ankara, Turkey

3 Molecular Histopathology, Pathology Department, Addenbrooke's Hospital, University of Cambridge Box 235, Level 3, Hills Road, Cambridge CB2 2QQ, UK

4 Wellcome/Cancer Research UK Gurdon Institute and Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QR, UK

5 Cambridge NTRAC Centre, Cambridge, UK

6 Ian Potter Centre for Cancer Genomics and Predictive Medicine, Peter MacCallum Cancer Centre, St. Andrew's Place, East Melbourne,Victoria 3002, Australia

For all author emails, please log on.

BMC Genomics 2006, 7:90  doi:10.1186/1471-2164-7-90

Published: 25 April 2006



Post-translational modification of histones resulting in chromatin remodelling plays a key role in the regulation of gene expression. Here we report characteristic patterns of expression of 12 members of 3 classes of chromatin modifier genes in 6 different cancer types: histone acetyltransferases (HATs)- EP300, CREBBP, and PCAF; histone deacetylases (HDACs)- HDAC1, HDAC2, HDAC4, HDAC5, HDAC7A, and SIRT1; and histone methyltransferases (HMTs)- SUV39H1and SUV39H2. Expression of each gene in 225 samples (135 primary tumours, 47 cancer cell lines, and 43 normal tissues) was analysedby QRT-PCR, normalized with 8 housekeeping genes, and given as a ratio by comparison with a universal reference RNA.


This involved a total of 13,000 PCR assays allowing for rigorous analysis by fitting a linear regression model to the data. Mutation analysis of HDAC1, HDAC2, SUV39H1, and SUV39H2 revealed only two out of 181 cancer samples (both cell lines) with significant coding-sequence alterations. Supervised analysis and Independent Component Analysis showed that expression of many of these genes was able to discriminate tumour samples from their normal counterparts. Clustering based on the normalized expression ratios of the 12 genes also showed that most samples were grouped according to tissue type. Using a linear discriminant classifier and internal cross-validation revealed that with as few as 5 of the 12 genes, SIRT1, CREBBP, HDAC7A, HDAC5 and PCAF, most samples were correctly assigned.


The expression patterns of HATs, HDACs, and HMTs suggest these genes are important in neoplastic transformation and have characteristic patterns of expression depending on tissue of origin, with implications for potential clinical application.